Patients receiving large amounts of interferon (IFN), particularly cloned IFN-alpha, have been reported to develop antibodies to IFN-alpha. We used a neutralization technique bioassay to monitor 175 patients undergoing recombinant (r) IFN-alpha 2b therapy in an attempt to correlate antibody production to disease progression. Only 1 patient being treated for chronic myelogenic leukemia produced antibodies. Our findings indicate that rIFN-alpha 2b has minimal antigenicity, even when administered for prolonged periods of time.
Low incidence of neutralizing antibody formation to interferon-alpha 2b in human recipients / Dianzani, F; Antonelli, Guido; Amicucci, P; Cefaro, A; Pintus, C.. - In: JOURNAL OF INTERFERON RESEARCH. - ISSN 0197-8357. - STAMPA. - 9 Suppl 1:(1989), pp. S33-S36.
Low incidence of neutralizing antibody formation to interferon-alpha 2b in human recipients.
ANTONELLI, Guido;
1989
Abstract
Patients receiving large amounts of interferon (IFN), particularly cloned IFN-alpha, have been reported to develop antibodies to IFN-alpha. We used a neutralization technique bioassay to monitor 175 patients undergoing recombinant (r) IFN-alpha 2b therapy in an attempt to correlate antibody production to disease progression. Only 1 patient being treated for chronic myelogenic leukemia produced antibodies. Our findings indicate that rIFN-alpha 2b has minimal antigenicity, even when administered for prolonged periods of time.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
